Federal Court upholds Alexion patent, blocks Amgen biosimilar launch until 2027
The Federal Court has upheld the validity of a patent held by Alexion Pharmaceuticals on a drug for the treatment of a rare blood disorder and granted an injunction blocking Amgen...To view the full article, register now.
Already a subscriber? Click here to view full article